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We report final event-driven analysis data on the immunogenicity and efficacy of the human papillomavirus 16 and 18 ((HPV-
16/18) AS04-adjuvanted vaccine in young women aged 15 to 25 years from the PApilloma TRIal against Cancer In young Adults
(PATRICIA). The total vaccinated cohort (TVC) included all randomized participants who received at least one vaccine dose
(vaccine, n 9,319; control, n 9,325) at months 0, 1, and/or 6. The TVC-naive (vaccine, n 5,822; control, n 5,819) had no
evidence of high-risk HPV infection at baseline, approximating adolescent girls targeted by most HPV vaccination programs.
Mean follow-up was approximately 39 months after the first vaccine dose in each cohort. At baseline, 26% of women in the TVC
had evidence of past and/or current HPV-16/18 infection. HPV-16 and HPV-18 antibody titers postvaccination tended to be
higher among 15- to 17-year-olds than among 18- to 25-year-olds. In the TVC, vaccine efficacy (VE) against cervical intraepithe-
lial neoplasia grade 1 or greater (CIN1), CIN2, and CIN3 associated with HPV-16/18 was 55.5% (96.1% confidence interval
[CI], 43.2, 65.3), 52.8% (37.5, 64.7), and 33.6% (1.1, 56.9). VE against CIN1, CIN2, and CIN3 irrespective of HPVDNA
was 21.7% (10.7, 31.4), 30.4% (16.4, 42.1), and 33.4% (9.1, 51.5) and was consistently significant only in 15- to 17-year-old
women (27.4% [10.8, 40.9], 41.8% [22.3, 56.7], and 55.8% [19.2, 76.9]). In the TVC-naive, VE against CIN1, CIN2, and
CIN3 associated with HPV-16/18 was 96.5% (89.0, 99.4), 98.4% (90.4, 100), and 100% (64.7, 100), and irrespective of HPVDNA
it was 50.1% (35.9, 61.4), 70.2% (54.7, 80.9), and 87.0% (54.9, 97.7). VE against 12-month persistent infection with HPV-16/18
was 89.9% (84.0, 94.0), and that against HPV-31/33/45/51 was 49.0% (34.7, 60.3). In conclusion, vaccinating adolescents before
sexual debut has a substantial impact on the overall incidence of high-grade cervical abnormalities, and catch-up vaccination up
to 18 years of age is most likely effective. (This study has been registered at ClinicalTrials.gov under registration no.
NCT001226810.)
Cervical cancer is the fourth most common cancer amongwomen, with estimates from 2012 indicating that there are
528,000 new cases and 266,000 deaths each year worldwide (1). It
is now established that persistent infection (PI) with human pap-
illomavirus (HPV) is a prerequisite for cervical cancer (2). Ap-
proximately 70% of cervical cancer cases are attributable to high-
risk (hr) HPV-16 and -18, with HPV-31, -33, -35, -45, -51, -52,
and -58 contributing to an additional 20% of cases (3).
The GSK group of companies have developed a prophylactic
vaccine against HPV types 16 and 18, formulated with the AS04
adjuvant system (containing aluminum hydroxide and 3-O-de-
sacyl-4= monophosphoryl lipid A). This vaccine is immunogenic
and efficacious andhas a clinically acceptable safety profile (4–11).
In the end-of-study analysis of the according-to-protocol cohort
from a large randomized, double-blind, controlled study (the
PApilloma TRIal against Cancer In young Adults [PATRICIA];
registration no. NCT001226810), high vaccine efficacy (VE) was
shown against PIs and high-grade cervical intraepithelial neopla-
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sia (CIN) associated with HPV-16 and/or HPV-18 (12). Cross-
protective efficacy was also shown against some phylogenetically
related and nonrelated nonvaccine hr HPV types (13).
The risk of HPV infection starts from the onset of sexual activ-
ity, and the rate of acquisition of infection is highest in adolescents
(14, 15). Therefore, the target population for current organized
public health vaccination programs is adolescent girls before sex-
ual debut, although a number of countries have also initiated
catch-up vaccination programs up to 26 years of age (16–19). In
this article, we provide data on the impact of the HPV-16/18
AS04-adjuvanted vaccine in a cohort of adolescent girls and young
women from PATRICIA (8), who at baseline had no DNA de-
tected for 14 hr HPV types, were seronegative for HPV-16 and
HPV-18, and who had normal cytology results. This total vacci-
nated, HPV-naive cohort (TVC-naive) immunologically and vi-
rologically approximates the target population of current vaccina-
tion programs in terms of exposure to and acquisition of HPV
types. To approximate the potential impact of catch-up vaccina-
tion, we also report results for the total vaccinated cohort (TVC),
which includes all women who received at least one vaccine dose
irrespective of their baseline cytological, serological, orHPVDNA
status and approximates the population of women targeted by
catch-up HPV vaccination programs.
The data summarized here are from the final event-driven
analysis of PATRICIA and include approximately 39 months of
follow-up. Data from a prespecified, descriptive end-of-study
analysis, which include follow-up to month 48, have been pub-
lished previously (12, 13). However, the final event-driven data
from the prespecified conclusive analysis, for which type I error
was controlled, are included in the vaccine prescribing informa-
tion in many countries and help to illustrate the high overall effi-
cacy of the HPV-16/18 AS04-adjuvanted vaccine. Here, we report
age-stratifiedVE against all grades of CIN associatedwithHPV-16
and/or -18 and irrespective of HPV type in the lesion, VE against
PIs with hr HPV types, and immunogenicity.
MATERIALS AND METHODS
Data are derived from the final event-driven analysis of PATRICIA, which
was a phase III, randomized, double-blind, controlled efficacy study (8,
12). The design of PATRICIAhas been reported previously, and the event-
driven analysis was the prespecified primary analysis (8).
Participants. Healthy women aged 15 to 25 years at the time of first
vaccinationwho reported nomore than six lifetime sexual partners before
study enrollment (this criterion was not applied to subjects aged 15 to 17
years in Finland) were enrolled regardless of their HPVDNA status, HPV
serostatus, or cytology at baseline. Since women were not asked to specify
the precise number of total lifetime sexual partners, this overall HPV
exposure variable was not ascertained. Written informed consent/assent
was obtained from all participants and/or their parents. The protocol and
other materials were approved by independent ethics committees or in-
stitutional review boards.
Procedures. Women were randomized in a 1:1 ratio to receive either
the HPV-16/18 AS04-adjuvanted vaccine (Cervarix; GSK group of com-
panies) or a control hepatitis A vaccine at 0, 1, and 6 months (8, 12). The
study protocol prescribed that both groups were to be unblinded follow-
ing the month 48 visit and offered the crossover vaccine. Further fol-
low-up of subjects enrolled in Finland is ongoing (20). Cervical sample
collection, HPV DNA testing, gynecological and cytopathological exami-
nations, assessment of cytology, and testing of cervical and biopsy samples
for the presence of DNA from 14 hr HPV types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, 66, and 68), using the broad-spectrum PCR SPF10
LiPA25 system (version 1 based on licensed Innogenetics SPF10 technol-
ogy; Labo Biomedical Products, Rijswijk, Netherlands), and type-specific
PCR forHPV-16 andHPV-18 were performed as described previously (8,
12, 21).HPVDNAdetected in the tissue biopsy specimenswas regarded as
associated with the lesion.
Antibodies against HPV-16 and HPV-18 were assessed by enzyme-
linked immunosorbent assay (ELISA) in a subset of women from selected
study sites (22). Seropositivity was defined as an antibody titer greater
than or equal to the assay cutoff: 8 ELISA units (EU)/ml for HPV-16 and
7 EU/ml for HPV-18.
Management of abnormal cytology results and colposcopy referral.
A prespecified clinical management algorithm for abnormal cytology re-
sults and colposcopy referral was employed. The colposcopy referral al-
gorithm was designed to capture the most clinically relevant lesions, i.e.,
those that were most likely to persist. Subjects with a normal Pap smear
underwent yearly scheduled cytological examinations. For a single obser-
vation of abnormal low-grade cytology, such as atypical squamous cells of
undetermined significance (ASC-US) with HPV DNA Hybrid Capture II
(HCII)-positive results (referred to as high-risk HPV probe positive or
HR) or low-grade squamous cell intraepithelial lesion (LSIL), the cytol-
ogy was to be repeated at the next scheduled study visit (6 months later).
Two observations (consecutive or intermittent) of low-grade cytology led
to a referral for colposcopy. Subjects with a single observation of high-
grade abnormal cytology (atypical squamous cells in which high-grade
squamous intraepithelial lesions could not be excluded [ASC-H], atypical
glandular cells of undetermined significance [AGC-US], or high-grade
squamous intraepithelial lesion [HSIL] or greater) were referred for im-
mediate colposcopy with cervical biopsy and, if appropriate, endocervical
specimen collection and further medical follow-up. In a protocol amend-
ment, the algorithm was updated to adapt to the evolution of standard
medical practices (23) to allow for women with ASC-US (HR or with
testing not performed) or LSIL to be immediately referred for colposcopic
evaluation at the discretion of the investigator.
Prespecified colposcopy management algorithms were employed in
which cytology and/or colposcopy had to be repeated for some outcomes
at the next scheduled study visit (6 months later). If the biopsy or endo-
cervical specimen results were negative orCIN grade 1 (CIN1) or if the
cytology result were LSIL, the cytology and colposcopy were to be re-
peated at 6 months. If the biopsy or the endocervical specimen result was
CIN grade 2 or greater ([CIN2], defined as CIN grade 2 [CIN2], CIN
grade 3 [CIN3], adenocarcinoma in situ [AIS], or invasive carcinoma) or
the cytology result wasHSIL, a loop electrosurgical excision procedure
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TABLE 1 Demographic and baseline characteristics
Cohort and parametera
Valueb for group
Total cohortc 15–17 yr 18–20 yr 21–25 yr
Vaccine Control Vaccine Control Vaccine Control Vaccine Control
TVC-naive
No. of subjects 5,822 5,819 2,063 2,081 1,206 1,257 2,543 2,476
Mean age (SD), yr 19.9 (3.2) 19.8 (3.1) 16.4 (0.6) 16.4 (0.6) 19.1 (0.8) 19.1 (0.8) 23.0 (1.4) 23.0 (1.4)
Region
Asia Pacific 2,203 (37.8) 2,134 (36.7) 121 (5.9) 115 (5.5) 486 (40.3) 516 (41.1) 1,588 (62.4) 1,498 (60.5)
Europe 2,173 (37.3) 2,209 (38.0) 1,719 (83.3) 1,738 (83.5) 184 (15.3) 195 (15.5) 269 (10.6) 276 (11.1)
North America 772 (13.3) 786 (13.5) 132 (6.4) 129 (6.2) 340 (28.2) 356 (28.3) 299 (11.8) 301 (12.2)
Latin America 674 (11.6) 690 (11.9) 91 (4.4) 99 (4.8) 196 (16.3) 190 (15.1) 387 (15.2) 401 (16.2)
Ever had sexual intercourse
Yes 4,655 (82.0) 4,674 (82.1) 1,352 (66.0) 1,357 (65.6) 996 (85.6) 1,056 (86.2) 2,298 (93.6) 2,256 (94.2)
No 1,020 (18.0) 1,017 (17.9) 695 (34.0) 711 (34.4) 167 (14.4) 168 (13.7) 157 (6.4) 138 (5.8)
No data 147 128 16 13 43 33 88 82
No. of sexual partners in last year
0 210 (4.5) 208 (4.5) 57 (4.2) 50 (3.7) 48 (4.8) 53 (5.0) 105 (4.6) 105 (4.7)
1 3,665 (78.9) 3,655 (78.4) 898 (66.6) 915 (67.6) 767 (77.2) 800 (76.2) 1,993 (87.0) 1,935 (85.9)
2 530 (11.4) 552 (11.8) 257 (19.1) 248 (18.3) 121 (12.2) 145 (13.8) 150 (6.5) 159 (7.1)
3 238 (5.1) 245 (5.3) 137 (10.2) 140 (10.3) 57 (5.7) 52 (5.0) 44 (1.9) 53 (2.4)
Not applicabled 1,020 1,017 695 711 167 168 157 138
No data 159 142 19 17 46 39 94 86
Chlamydia trachomatise
Negative 5,225 (96.5) 5,224 (96.5) 1,943 (98.7) 1,955 (98.8) 1,046 (94.8) 1,124 (95.5) 2,230 (95.4) 2,140 (94.9)
Positive 191 (3.5) 191 (3.5) 25 (1.3) 24 (1.2) 57 (5.2) 53 (4.5) 107 (4.6) 114 (5.1)
No data 406 404 95 102 103 80 206 222
Contraceptive usef
Hormonal 3,107 (53.4) 3,236 (55.6) 862 (41.8) 895 (43.0) 723 (60.0) 792 (63.0) 1,515 (59.6) 1,547 (62.5)
Intrauterine device 311 (5.3) 259 (4.5) 5 (0.2) 4 (0.2) 47 (3.9) 43 (3.4) 259 (10.2) 211 (8.5)
Sterilized 59 (1.0) 48 (0.8) 1 (0.1) 1 (0.1) 5 (0.4) 3 (0.2) 52 (2.0) 44 (1.8)
Smoking status
Never smoked or smoked for6 mo 4,253 (74.9) 4,221 (74.1) 1,395 (68.1) 1,403 (67.8) 900 (77.4) 935 (76.3) 1,950 (79.4) 1,880 (78.5)
Smoker for6 mo (current or past) 1,422 (25.1) 1,472 (25.9) 652 (31.9) 666 (32.2) 263 (22.6) 290 (23.7) 505 (20.6) 514 (21.5)
No data 147 126 16 12 43 32 88 82
TVC
No. of subjects 9,319 9,325 2,973 2,984 2,065 2,095 4,269 4,236
Mean age (SD), yr 20.0 (3.1) 20.0 (3.1) 16.4 (0.6) 16.4 (0.6) 19.1 (0.8) 19.1 (0.8) 23.0 (1.4) 23.0 (1.4)
Region
Asia Pacific 3,175 (34.1) 3,177 (34.1) 164 (5.5) 179 (6.0) 743 (36.0) 760 (36.3) 2,258 (52.9) 2,229 (52.6)
Europe 3,224 (34.6) 3,224 (34.6) 2,448 (82.3) 2,451 (82.1) 310 (15.0) 309 (14.7) 465 (10.9) 464 (11.0)
North America 1,532 (16.4) 1,538 (16.5) 201 (6.8) 196 (6.6) 617 (29·9) 646 (30.8) 713 (16·7) 695 (16.4)
Latin America 1,388 (14.9) 1,386 (14.9) 160 (5.4) 158 (5.3) 395 (19.1) 380 (18.1) 833 (19.5) 848 (20.0)
Ever had sexual intercourse
Yes 7,924 (87.0) 7,936 (87.1) 2,152 (72.9) 2,142 (72.3) 1,810 (90.3) 1,835 (90.2) 3,951 (95.5) 3,949 (96.2)
No 1,183 (13.0) 1,176 (12.9) 800 (27.1) 820 (27.7) 194 (9.7) 198 (9.7) 188 (4.5) 158 (3.8)
No data 212 213 21 22 61 62 130 129
No. of sexual partners in last year
0 294 (3.7) 292 (3.7) 73 (3.4) 59 (2.8) 68 (3.8) 73 (4.0) 153 (3.9) 160 (4.1)
1 5,862 (74.1) 5,869 (74.1) 1,291 (60.1) 1,288 (60.2) 1,300 (72.0) 1,324 (72.5) 3,262 (82.8) 3,248 (82.4)
2 1,114 (14.1) 1,161 (14.7) 433 (20.1) 462 (21.6) 285 (15.8) 302 (16.5) 394 (10.0) 397 (10.1)
3 636 (8.0) 595 (7.5) 352 (16.4) 329 (15.4) 153 (8.5) 128 (7.0) 131 (3.3) 137 (3.5)
Not applicabled 1,183 1,176 800 820 194 198 188 158
No data 230 232 24 26 65 70 141 136
Chlamydia trachomatise
Negative 8,155 (94.5) 8,188 (94.5) 2,748 (97.3) 2,758 (97.4) 1,740 (91.7) 1,817 (92.9) 3,659 (93.8) 3,604 (93.3)
Positive 478 (5.5) 475 (5.5) 76 (2.7) 75 (2.6) 157 (8.3) 139 (7.1) 243 (6.2) 260 (6.7)
No data 686 662 149 151 168 139 367 372
Contraceptive usef
Hormonal 5,544 (59.5) 5,662 (60.7) 1,416 (47.6) 1,452 (48.7) 1,357 (65.7) 1,410 (67.3) 2,763 (64.7) 2,795 (66.0)
Intrauterine device 501 (5.4) 472 (5.1) 7 (0.2) 6 (0.2) 83 (4.0) 86 (4.1) 411 (9.6) 379 (8.9)
Sterilized 105 (1.1) 96 (1.0) 1 (0.0) 2 (0.1) 6 (0.3) 4 (0.2) 96 (2.2) 90 (2.1)
(Continued on following page)
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or cone biopsy was to be performed. Furthermanagement was performed
according to local medical practice.
Statistical analysis. This was an event-driven analysis study with a
fixed sample size. The final analysis was triggered when a prespecified
number of endpoints was reached (at least 36 cases of CIN2 associated
with HPV-16/18, including at least 15 cases of CIN2 associated with
HPV-18) in the according-to-protocol cohort for efficacy, as defined pre-
viously (8). The TVC included all women who received at least one vac-
cine dose and were evaluable for efficacy (i.e., had a baseline PCR or
cytology sample and one further sample available). The TVC-naive in-
cludedwomenwho received at least one vaccine dose, were DNAnegative
for all 14 hr HPV types investigated and seronegative for HPV-16 and
HPV-18, and had normal cytology at baseline.Women infected with low-
riskHPV types onlywere not excluded. Follow-up for eachwoman started
on the day after administration of the first dose of study vaccine. Any
lesions diagnosed as a result of abnormal cytology or any infections de-
tected at the first visit were included in the outcome analysis. Follow-up
time for each analysis ended (i) at the time of an event (e.g., detection of
CIN2 or start of PI), (ii) for those who did not have an event and who
completed the study, at 48months after administration of the first vaccine
dose, or (iii) for those who did not have an event and who were active in
the study at the time this present final event-driven analysis was per-
formed, at the date of the last visit for which a biopsy, cytology, or PCR
sample was available.
Histopathological and virological efficacy outcomes were evaluated as
described previously (8, 12). We evaluated VE against CIN1, CIN2,
and CIN3 associated with HPV-16 or HPV-18 DNA in the lesion and
against CIN1, CIN2, and CIN3 irrespective of HPV DNA (this in-
cluded all lesions regardless of whether an HPV type was detected). We
also evaluated VE against 6-month and 12-month PIs associated with
vaccine HPV types (HPV-16/18), common nonvaccine hr HPV types
(HPV-31/33/45/51), and any hr HPV type (HPV-16/18/31/33/35/39/45/
51/52/56/58/59/66/68). Additionally, we stratified efficacy analyses by age
(15 to 17, 18 to 20, or 21 to 25 years). Analyses were prespecified, except
for cross-protective efficacy against PIs with the combination of nonvac-
cine HPV types 31/33/45/51, against which consistent cross-protection
against virological and clinical endpoints was shown in the 4-year end-of-
study analysis (12, 13).
VE was calculated with a conditional exact method (see the supple-
mental material for details). For all endpoints, the overall alpha of 0.05
was divided into 0.021 for the interim analysis (97.9% confidence interval
[CI]) and 0.039 for the final analysis (96.1%CI). The 96.1%CIs presented
could be interpreted as 95% CIs to limit the overall type one error to 5%.
For the final analysis, significance was defined when the lower limit of the
96.1%CI for VEwas greater than 30.0% for CIN2 associatedwithHPV-
16/18 and greater than zero for all other endpoints. Event rates were cal-
culated as the number of cases divided by the sum of the follow-up period
in years for each group and are expressed per 100 woman-years.
HPV-16 and HPV-18 geometric mean antibody titers (GMTs) with
95% CI were calculated for the vaccine group. In an exploratory post hoc
analysis, we stratified GMT data by age (15 to 17 or 18 to 25 years) and by
number of reported sexual partners in the year prior to study (0, 1 or 2, or
3 partners). For the GMT calculations, seronegative women were as-
signed a value of half the assay cutoff level.
For VE against 6-month and 12-month PI, we performed an addi-
tional exploratory analysis which excluded those women in the TVC-
naive at baseline. This cohort (TVC baseline positive), represents women
who had evidence of past and/or current HPV infection or lesions at
baseline.
Statistical analyses were done with Statistical Analysis System (SAS)
9.2 and Proc StatXact-7.
RESULTS
Study population. Totals of 11,641 and 18,644 women were in-
cluded in the TVC-naive and TVC, respectively. Demographic
and baseline characteristics for these cohorts are shown in Table 1,
together with characteristics by age strata (36% and 32% were
aged 15 to 17 years, 21% and 22% aged 18 to 20 years, and 43%
and 46% aged 21 to 25 years in the TVC-naive and TVC, respec-
tively). The mean ages at first vaccination were 19.8 years (TVC-
naive) and 20.0 years (TVC). Compliance with completion of the
three-dose vaccination schedule was high (92% in each group).
Approximately 8% and 10% of subjects were withdrawn from the
TVC-naive and TVC, respectively, at the time of the final event-
triggered analysis. The numbers of subjects who did not complete
the study were balanced between the vaccine and control groups.
At the time of the final event-driven analysis, the mean durations
of follow-up for the TVC-naive and TVC were 39.5 (standard
deviation [SD], 9.0) and 39.4 (SD, 9.7) months, respectively.
Overall, subjects were predominantly from Europe and Asia
Pacific (35% and 34%, respectively, in the TVC), with some dif-
ferences among the age groups in the geographical distribution of
participants. Most notably, 80% of 15- to 17-year-olds were from
Finland. Finnish participants were recruited exclusively at
schools, as described previously (20). Thirty-six percent of all 18-
to 20-year-olds and 53% of all 21- to 25-year-olds were from Asia
Pacific.
At baseline, the overall study population (TVC) was predom-
inantly sexually active, and only 13% reported that they had never
had sexual intercourse (defined as penetrative or genital-to-geni-
tal sexual contact) (Table 1). Only 4% of those who reported prior
sexual activity indicated no sexual partner in the year prior to the
study, while 74% indicated one sexual partner. More 15- to 17-
TABLE 1 (Continued)
Cohort and parametera
Valueb for group
Total cohortc 15–17 yr 18–20 yr 21–25 yr
Vaccine Control Vaccine Control Vaccine Control Vaccine Control
Smoking status
Never smoked or smoked for6 mo 6,401 (70.3) 6,388 (70.1) 1,840 (62.3) 1,867 (63.0) 1,471 (73.4) 1,469 (72.2) 3,080 (74.4) 3,405 (74.1)
Smoker for6 mo (current or past) 2,706 (29.7) 2,726 (29.9) 1,112 (37.7) 1,096 (37.0) 533 (26.6) 565 (27.8) 1,059 (25.6) 1,062 (25.9)
No data 212 211 21 21 61 61 130 129
a TVC, total vaccinated cohort. TVC-naive, total vaccinated cohort of women who at baseline had no DNA detected for 14 high-risk HPV types, were seronegative for HPV-16 and
HPV-18, and had normal cytology results.
b Data are number of subjects (percentage) unless indicated otherwise. Where data were missing, percentages were calculated from data available.
c Twenty-two subjects in the TVC and 15 subjects in the TVC-naive were aged15 years or25 years at time of first vaccination and are not included in an age stratum.
d Responded “no” to the question, “Have you ever had sexual intercourse?”
e Chlamydia trachomatis detected in cervical samples by PCR (Cobas Amplicor, Roche).
f Women may have used more than one method of contraception or a method that is not listed.
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year-olds (27%) than 18- to 20-year-olds (10%) or 21- to 25-year-
olds (4%) reported that they had never had sexual intercourse, but
a greater proportion of the 15- to 17-year-olds who did report
sexual intercourse had more than one partner in the year prior to
the study, compared to 18- to 20-year-olds or 21- to 25-year-olds
(21%, 16%, and 10% for two partners and 16%, 8%, and 3% for
three partners, respectively). In the TVC-naive, a larger propor-
tion of 15- to 17-year-olds than of 18- to 20- or 21- to 25-year-olds
reported that they had never had sexual intercourse (34%, 14%,
and 6%, respectively). Of those baseline negative women with
reported data regarding sexual intercourse, a larger proportion of
15- to 17-year-olds than of 18- to 20- or 21- to 25-year-olds re-
ported at least three sexual partners in the last year (10%, 5%, and
2%, respectively), and a smaller proportion reported only one
sexual partner (67%, 77%, and 86%, respectively).
In both cohorts, a smaller proportion of 15- to 17-year-olds
than of 18- to 20- or 21- to 25-year-olds reported that they had
never smoked or had smoked for6 months. Chlamydia tracho-
matis positivity was approximately 2 to 4 times higher in the older
age groups than in the 15- to 17-year-olds.
Approximately one-quarter of women in the TVC (26%) had
evidence of past and/or current HPV-16 and/or -18 infection (se-
ropositive and/orHPVDNApositive for at least one of the vaccine
HPV types) at baseline (see Table S1 in the supplemental mate-
rial).When stratified by age, a higher proportion of 18- to 20-year-
olds (27%) and 21- to 25-year-olds (30%) had evidence of past
and/or current HPV-16/18 infection compared with 15- to 17-
year-olds (20%). Approximately 5% of these women were
HPV-16DNApositive and approximately 2%wereHPV-18DNA
positive at baseline, with fewer than 1% positive for both HPV
types (data not shown). Approximately 20%of womenwereDNA
positive for at least one hr HPV type at baseline. Baseline seropos-
itivity was 17% for HPV-16 and 12% for HPV-18. At baseline,
over 90% of the women had normal cytology, 9% had ASC-US
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FIG 1 Geometric mean antibody titers measured by ELISA in the vaccine group, according to age and reported number of sexual partners in the year prior to
study, againstHPV-16 andHPV-18 in the TVC-naive (A andC, respectively) and the TVC (B andD, respectively). Bars show log10 geometricmean antibody titer
(GMT) and 95% confidence interval. For the GMT calculation, seronegative women were assigned a value of half the assay cutoff level. M, month.
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(regardless of HCII result) or LSIL and 0.5% had high-grade cy-
tology (HSIL, ASC-H AGC) (see Table S2 in the supplemental
material). Baseline cytology status was similar in each stratum. A
total of 7,003 (38%) women had evidence of past and/or current
HPV infection or lesions at baseline (i.e., DNA positive for at least
one of the 14 hrHPV types, seropositive forHPV-16 and/orHPV-
18, or abnormal cytology at baseline).
Immunogenicity. In both cohorts, following an initial peak at
month 7, HPV-16 andHPV-18 GMTs were sustained throughout
36 months of follow-up (Fig. 1). In the TVC-naive for women
aged 15 to 17 years, HPV-16 and HPV-18 peak GMTs at month 7
tended to increase by number of sexual partners in the year prior
to study at all postvaccination time points, although 95% CIs for
GMTs overlapped for all groups. In contrast, in the TVC, among
adult women aged 18 to 25 years, peak HPV-16 and -18 GMTs at
month 7 tended to be the lowest in individuals with higher num-
bers of sexual partners in the year prior to vaccination. However,
the 95% CIs overlapped for all groups, and these tendencies were
not statistically significant even in the population of TVC women
whohad evidence of past and/or currentHPV infection at baseline
(HPV DNA positive and/or seropositive for HPV-16 or HPV-18
and/or abnormal cytology at baseline) (data not shown).
Efficacy against PI. VE against persistent infection (PI) with
vaccine HPV-16/18 was higher than that against nonvaccine hr
HPV types (Table 2). However, in the TVC-naive we still observed
statistically significant cross-protective VE against persistent
6-month and 12-month infections, both with a combination of
nonvaccine HPV-31/33/45/51 (42.5% [96.1% CI, 32.9 to 50.9]
and 49.0% [34.7 to 60.3], respectively) and with any hr HPV type
(33.5% [26.9 to 39.6] and 36.7% [27.4 to 44.9], respectively).With
the exception of VE against 12-month PI with HPV-31/33/45/51
in 18- to 20-year-old women, this was true for all age groups in the
TVC-naive, albeit at a lower level than corresponding VE against
PIs with HPV-16/18.
In the TVC, VE against 6-month and 12-month PIs with vac-
cine or nonvaccine hr HPV types was highest for women aged 15
to 17 years (Table 2). In women aged 18 to 20 years and 21 to 25
years, statistically significant VEwas shown against PIs withHPV-
16/18 and with any hr HPV type but was not consistently shown
for PIswith nonvaccineHPV-31/33/45/51. In the baseline positive
subset of women in the TVC, who had evidence of past and/or
current HPV infection, no cross-protective VE was observed
against 6-month or 12-month PIs with HPV-31/33/45/51 or any
hr HPV type in women aged 18 to 25 years (Table 2).
Efficacy against cervical intraepithelial neoplasia. In the
TVC-naive, a total of 88 CIN1 cases associated with HPV-16
and/or HPV-18 were identified (including 64 CIN2 and 13
CIN3, of which 3were adenocarcinoma in situ [AIS]) during the
follow-up period (Table 3). VE against CIN1, CIN2, and
CIN3 associated with HPV-16 and/or -18 was 96.5% (89.0 to
99.4), 98.4% (90.4 to 100), and 100% (64.7 to 100), respectively.
In the TVC, a total of 347 CIN1 cases associated with HPV-16
and/or HPV-18 were identified (including 256 CIN2 and 108
CIN3, of which 5 were AIS [all in the control group]) (Table 3).
The majority of the CIN2 lesions were associated with HPV-16
(227/256, 87%). In 28.6% of the 256 CIN2 cases associated with
HPV-16 and/or HPV-18, DNA from nonvaccine hr HPV types
was also detected. VE against CIN1, CIN2, and CIN3 asso-
ciated with HPV-16 and/or -18 was 55.5% (43.2 to 65.3), 52.8%
(37.5 to 64.7), and 33.6% (1.1 to 56.9), respectively.21
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TABLE 3 Efficacy against CIN1, CIN2, and CIN3 associated with HPV-16 and/or -18, stratified by agea
Age stratum Endpoint HPV typeb Group
TVC-naive TVC
n
No. of
cases Rate Efficacy (96.1% CI) n
No. of
cases Rate Efficacy (96.1% CI)
All CIN1 HPV-16/18 Vaccine 5,449 3 0.02 96.5 (89.0, 99.4) 8,667 107 0.43 55.5 (43.2, 65.3)
Control 5,436 85 0.54 8,682 240 0.97
HPV-16 Vaccine 5,449 2 0.01 97.3 (89.3, 99.7) 8,667 90 0.36 54.5 (40.6, 65.4)
Control 5,436 73 0.46 8,682 198 0.80
HPV-18 Vaccine 5,449 1 0.01 94.5 (62.8, 99.9) 8,667 18 0.07 70.4 (48.0, 84.1)
Control 5,436 18 0.11 8,682 61 0.24
CIN2 HPV-16/18 Vaccine 5,449 1c 0.01 98.4 (90.4, 100) 8,667 82 0.33 52.8 (37.5, 64.7)
Control 5,436 63 0.40 8,682 174 0.70
HPV-16 Vaccine 5,449 1c 0.01 98.2 (89.1, 100) 8,667 75 0.30 50.6 (33.5, 63.6)
Control 5,436 56 0.36 8,682 152 0.61
HPV-18 Vaccine 5,449 0 0.00 100 (61.3, 100) 8,667 8 0.03 75.7 (44.4, 90.8)
Control 5,436 12 0.08 8,682 33 0.13
CIN3 HPV-16/18 Vaccine 5,449 0 0.00 100 (64.7, 100) 8,667 43 0.17 33.6 (1.1, 56.9)
Control 5,436 13 0.08 8,682 65 0.26
HPV-16 Vaccine 5,449 0 0.00 100 (57.1, 100) 8,667 41 0.16 31.4 (5.9, 56.0)
Control 5,436 11 0.07 8,682 60 0.24
HPV-18 Vaccine 5,449 0 0.00 100 (170.8, 100) 8,667 2 0.01 77.7 (14.7, 98.0)
Control 5,436 3 0.02 8,682 9 0.04
15–17 yr CIN1 HPV-16/18 Vaccine 1,996 1 0.02 97.6 (85.0, 100) 2,880 28 0.32 73.6 (58.8, 83.7)
Control 2,022 42 0.68 2,891 106 1.22
HPV-16 Vaccine 1,996 1 0.02 97.0 (81.2, 99.9) 2,880 25 0.29 71.2 (53.7, 82.8)
Control 2,022 34 0.55 2,891 87 1.00
HPV-18 Vaccine 1,996 0 0.00 100 (64.1, 100) 2,880 4 0.05 87.5 (63.1, 97.0)
Control 2,022 13 0.21 2,891 32 0.36
CIN2 HPV-16/18 Vaccine 1,996 1c 0.02 96.6 (78.5, 99.9) 2,880 19 0.22 72.8 (53.2, 85.0)
Control 2,022 30 0.49 2,891 70 0.80
HPV-16 Vaccine 1,996 1c 0.02 95.8 (72.5, 99.9) 2,880 18 0.21 69.9 (47.0, 83.8)
Control 2,022 24 0.39 2,891 60 0.69
HPV-18 Vaccine 1,996 0 0.00 100 (51.0, 100) 2,880 2 0.02 87.4 (43.5, 98.8)
Control 2,022 10 0.16 2,891 16 0.18
CIN3 HPV-16/18 Vaccine 1,996 0 0.00 100 (23.2, 100) 2,880 6 0.07 74.9 (34.3, 92.1)
Control 2,022 7 0.11 2,891 24 0.27
HPV-16 Vaccine 1,996 0 0.00 100 (5.7, 100) 2,880 6 0.07 72.6 (27.3, 91.4)
Control 2,022 6 0.10 2,891 22 0.25
HPV-18 Vaccine 1,996 0 0.00 100 (527.0, 100) 2,880 0 0.00 100 (68.8, 100)
Control 2,022 2 0.03 2,891 4 0.05
18–20 yr CIN1 HPV-16/18 Vaccine 1,090 0 0.00 100 (83.0, 100) 1,862 30 0.58 55.7 (29.6, 72.8)
Control 1,139 26 0.81 1,902 69 1.31
HPV-16 Vaccine 1,090 0 0.00 100 (81.5, 100) 1,862 23 0.44 60.3 (33.1, 77.2)
Control 1,139 24 0.75 1,902 59 1.12
HPV-18 Vaccine 1,090 0 0.00 100 (183.7, 100) 1,862 7 0.13 52.3 (29.8, 84.5)
Control 1,139 3 0.09 1,902 15 0.28
CIN2 HPV-16/18 Vaccine 1,090 0 0.00 100 (78.5, 100) 1,862 21 0.40 61.9 (34.4, 78.7)
Control 1,139 21 0.66 1,902 56 1.06
HPV-16 Vaccine 1,090 0 0.00 100 (77.3, 100) 1,862 18 0.35 63.3 (34.3, 80.5)
Control 1,139 20 0.63 1,902 50 0.94
HPV-18 Vaccine 1,090 0 0.00 100 (544.0, 100) 1,862 3 0.06 69.4 (26.1, 95.1)
Control 1,139 2 0.06 1,902 10 0.19
CIN3 HPV-16/18 Vaccine 1,090 0 0.00 100 (75.1, 100) 1,862 10 0.19 51.4 (11.9, 80.5)
Control 1,139 4 0.12 1,902 21 0.40
HPV-16 Vaccine 1,090 0 0.00 100 (183.7, 100) 1,862 9 0.17 51.7 (16.6, 81.7)
Control 1,139 3 0.09 1,902 19 0.36
HPV-18 Vaccine 1,090 0 0.00 100 (5,157.1, 100) 1,862 1 0.02 65.9 (372.9, 99.5)
Control 1,139 1 0.03 1,902 3 0.06
21–25 yr CIN1 HPV-16/18 Vaccine 2,356 2 0.03 88.8 (50.0, 98.9) 3,916 49 0.45 25.3 (12.0, 50.6)
Control 2,271 17 0.27 3,880 65 0.60
(Continued on following page)
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In age-stratified analyses for baseline negative women (TVC-
naive), VE against HPV-16/18-associated CIN2 was 96.6%
(78.5 to 99.9) for women aged 15 to 17 years, 100% (78.5 to 100)
for women aged 18 to 20 years, and 100% (62.9 to 100) for women
aged 21 to 25 years (Table 3). In the TVC, VE against HPV-16/18-
associated CIN2was 72.8% (53.2 to 85.0) for women aged 15 to
17 years and 61.9% (34.4 to 78.7) for women aged 18 to 20 years
butwas negligible forwomen aged 21 to 25 years (13.2% [37.1 to
45.3]).
To assess the potential public health benefit of the vaccine, we
also evaluated efficacy against CIN, irrespective of HPVDNA type
in the lesion (Table 4). In the TVC-naive, a total of 317 CIN1
cases, irrespective of HPV DNA, were identified (including 143
CIN2 and 26 CIN3, of which 3 were AIS). VE increased with
increasing lesion severity: 50.1% (35.9 to 61.4) for CIN1, 70.2%
(54.7 to 80.9) for CIN2, and 87.0% (54.9 to 97.7) for CIN3. In
the age-stratified analysis, estimates of VEwere similar in the three
age strata and statistically significant against all grades of CIN in
women aged 15 to 17 years. Cases of CINwere limited in numbers
in the older age groups, and statistically significant VE was not
attained against CIN3 in women aged 18 to 20 years or against
CIN2 or CIN3 in women aged 21 to 25 years, although point
estimates of vaccine efficacy ranged from 57 to 100% (Table 4).
In the TVC a total of 1028 CIN1 cases irrespective of HPV
DNA in the lesion were identified (including 546 CIN2 and 193
CIN3, of which 9 were AIS [2 in the vaccine group and 7 in the
control group]) (Table 4). VE irrespective of HPV DNA in the
lesion was 30.4% (16.4 to 42.1) against CIN2 and 33.4% (9.1 to
51.5) against CIN3. As previously noted for HPV-16/18-associ-
ated lesions, low or negligible efficacy was shown in women aged
21 to 25 years against CIN2 (0.2% [37.0 to 26.7]) or CIN3
(3.2% [57.1 to 40.4]) irrespective of DNA in the lesion.
DISCUSSION
We examined the impact of theHPV-16/18 AS04-adjuvanted vac-
cine on women aged 15 to 25 years from PATRICIA, either those
who at baseline had no evidence of hr HPV infection (TVC-na-
ive), approximating the population of adolescent girls targeted by
HPV vaccination programs, or all vaccinated women in the study
(TVC).We build on previously published findings (7, 8, 12, 13) by
reporting data from the final, prespecified event-driven analysis
regarding age-stratified immunogenicity and efficacy against per-
sistent hr HPV infections and all grades of CIN associated with
HPV-16 and/or -18 and also irrespective of HPV type.
In the TVC-naive, we confirmed the high efficacy of the HPV-
16/18 AS04-adjuvanted vaccine in preventing lesions associated
withHPV-16 and/orHPV-18. Efficacywas 96.5% against CIN1,
98.4%against CIN2, and 100%against the immediate precursor
of invasive cervical cancer, CIN3. These results are generally in
line with published data regarding efficacy due to vaccine types for
the licensed quadrivalent HPV-6/11/16/18 vaccine in a similar
cohort of women, despite there being differences in methodolo-
gies between these studies (24, 25).
In the TVC, the vaccine prevented approximately 56% and
53%of CIN1 andCIN2 associatedwith vaccine typesHPV-16
and/or -18, respectively, compared with the control. Although
direct comparison of studies with differences inmethodology and
populations can be subject to a variety of issues, the estimate
against CIN2 is within the same range as previously reported in
studies with the licensed quadrivalent HPV vaccine in an equiva-
lent population (24, 26–28). Efficacy against CIN3 associated
with HPV-16 and/or -18 was 34% across all ages but was not
significant. Uniform, statistically significant VE against HPV-16/
18-associated CIN1, CIN2, and CIN3 was observed in the
TABLE 3 (Continued)
Age stratum Endpoint HPV typeb Group
TVC-naive TVC
n
No. of
cases Rate Efficacy (96.1% CI) n
No. of
cases Rate Efficacy (96.1% CI)
HPV-16 Vaccine 2,356 1 0.02 93.6 (55.9, 99.9) 3,916 42 0.39 19.9 (25.3, 49.1)
Control 2,271 15 0.24 3,880 52 0.48
HPV-18 Vaccine 2,356 1 0.02 52.1 (959.2, 99.4) 3,916 7 0.06 50.5 (37.2, 84.0)
Control 2,271 2 0.03 3,880 14 0.13
CIN2 HPV-16/18 Vaccine 2,356 0 0.00 100 (62.9, 100) 3,916 42 0.39 13.2 (37.1, 45.3)
Control 2,271 12 0.19 3,880 48 0.44
HPV-16 Vaccine 2,356 0 0.00 100 (62.9, 100) 3,916 39 0.36 7.9 (49.4, 43.3)
Control 2,271 12 0.19 3,880 42 0.39
HPV-18 Vaccine 2,356 0 0.00 3,916 3 0.03 57.5 (98.7, 93.6)
Control 2,271 0 0.00 3,880 7 0.06
CIN3 HPV-16/18 Vaccine 2,536 0 0.00 100 (490.4, 100) 3,916 27 0.25 34.1 (160.6, 29.7)
Control 2,271 2 0.12 3,880 20 0.18
HPV-16 Vaccine 2,536 0 0.00 100 (490.4, 100) 3,916 26 0.24 35.9 (168.6, 29.8)
Control 2,271 2 0.12 3,880 19 0.17
HPV-18 Vaccine 2,536 0 0.00 3,916 1 0.01 50.4 (996.4, 99.4)
Control 2,271 0 0.00 3,880 2 0.02
a n, number of evaluable women in each group; no. of cases, number of evaluable women reporting at least one event; rate, number of cases divided by sum of follow-up period
(per 100 person-years), where follow-up period started on the day after the first vaccine dose; TVC, total vaccinated cohort; TVC-naive, total vaccinated cohort of women who at
baseline had no DNA detected for 14 high-risk HPV types, were seronegative for HPV-16 and HPV-18, and had normal cytology results.
b Women were infected with one or both HPV types (thus, the number of women with an HPV-16-associated lesion and the number with an HPV-18-associated lesion might not
equal number with an HPV-16/18-associated lesion).
c This young woman acquired the HPV-16 responsible for development of the lesion prior to completion of the full three-dose series (HPV-16 DNA was detected at months 6, 12,
and 18; the CIN2 lesion was detected at month 21, and HPV-16 DNA was the only type in the lesion).
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15- to 17-year-old stratum only (74%, 73%, and 75%, respec-
tively).
An important public health aspect of our analysis was to eval-
uate overall efficacy of the HPV-16/18 AS04-adjuvanted vaccine
against clinical lesions without taking into consideration HPV
DNA testing results, as nonvaccine hr HPV types also contribute
to at least 20%of the burden of cervical disease (3). The overall VE
in the TVC-naive, irrespective of HPV DNA results, was 50%,
70%, and 87% against CIN1, CIN2, and CIN3, respectively.
In the TVC, irrespective of HPV DNA in the lesion, the vaccine
prevented 30% and 33% of high-grade cervical lesions (CIN2
and CIN3), respectively. Reductions of 42% and 44% were ob-
served in 15- to 17-year-olds and in 18- to 20-year-olds, respec-
tively, but none was observed for 21- to 25-year-olds. The lower
efficacy in the oldest age group could be due to a larger proportion
of women in this group with prevalent infections at baseline,
which the vaccine does not impact (29). The higher efficacy esti-
mates in CIN2 and CIN3 reflect the increasing relative prev-
alence of HPV-16 and -18 compared to some other hr HPV types
with increasing lesion severity (30–32) but also the consistent
cross-protective efficacy of the HPV-16/18 AS04-adjuvanted vac-
cine against HPV-31, -33, -45, and -51 (8, 13), which may extend
even further (33, 34).
To obtain the greatest benefit from prophylaxis, most HPV
vaccination programs target young adolescents with the aim of
immunizing before HPV exposure through sexual contact (15–
17). As there are no clinical efficacy studies with HPV vaccines in
the target population, the TVC-naive cohort from PATRICIAwas
used as an approximation of HPV-naive adolescents, by including
only study participants who at baseline had no evidence of expo-
sure to any of 14 hr HPV types detected by PCR, seronegativity to
HPV-16/18, and no evidence of cytological abnormalities. We
chose the age strata to reflect the variability in currently imple-
mented HPV vaccination programs, some of which (assuming
high compliance to the three-dose schedule) recommend
catch-up vaccination to 17 years of age and others through 25 to
26 years of age. In modeling and cost-benefit analyses, 18 years is
generally considered to be the upper age limit at which HPV vac-
cines are considered to be cost-effective (35, 36). The incidences of
CIN lesions associated with HPV-16/18, or irrespective of HPV
DNA, were consistently higher in women 15 to 17 years than in
women 21 to 25 years, but observed estimates of VE against CIN
and persistent hr HPV infections were similar in each age group.
At present, no conventionalmethod exists to assign lesion cau-
sality when several HPV types are detected. The complexities of
evaluating cross-protective efficacy against CIN lesions are ad-
TABLE 4 Efficacy against CIN1, CIN2, and CIN3, stratified by age, irrespective of HPV type in the lesiona
Age stratum Endpoint Group
TVC-naive TVC
n
No. of
cases Rate Efficacy (96.1% CI) n
No. of
cases Rate Efficacy (96.1% CI)
All CIN1 Vaccine 5,449 106 0.67 50.1 (35.9, 61.4) 8,667 451 1.85 21.7 (10.7, 31.4)
Control 5,436 211 1.35 8,682 577 2.37
CIN2 Vaccine 5,449 33 0.21 70.2 (54.7, 80.9) 8,667 224 0.91 30.4 (16.4, 42.1)
Control 5,436 110 0.70 8,682 322 1.31
CIN3 Vaccine 5,449 3b 0.02 87.0 (54.9, 97.7) 8,667 77 0.31 33.4 (9.1, 51.5)
Control 5,436 23 0.15 8,682 116 0.47
15–17 yr CIN1 Vaccine 1,996 51 0.85 52.2 (31.5, 67.0) 2,880 182 2.15 27.4 (10.8, 40.9)
Control 2,022 108 1.77 2,891 252 2.96
CIN2 Vaccine 1,996 20 0.33 67.8 (44.7, 82.1) 2,880 84 0.98 41.8 (22.3, 56.7)
Control 2,022 63 1.03 2,891 145 1.68
CIN3 Vaccine 1,996 2 0.03 85.5 (33.1, 98.6) 2,880 18 0.21 55.8 (19.2, 76.9)
Control 2,022 14 0.23 2,891 41 0.47
18–20 yr CIN1 Vaccine 1,090 25 0.82 46.9 (10.2, 69.4) 1,862 110 2.17 23.6 (0.2, 41.6)
Control 1,139 49 1.55 1,902 147 2.84
CIN2 Vaccine 1,090 5 0.16 82.1 (51.2, 94.9) 1,862 46 0.89 44.2 (17.7, 62.7)
Control 1,139 29 0.91 1,902 84 1.60
CIN3 Vaccine 1,090 1 0.03 82.6 (55.0, 99.7) 1,862 19 0.21 43.0 (5.8, 70.3)
Control 1,139 6 0.19 1,902 34 0.44
21–25 yr CIN1 Vaccine 2,356 30 0.45 46.9 (13.6, 68.0) 3,916 159 1.48 11.7 (11.3, 30.0)
Control 2,271 54 0.85 3,880 178 1.67
CIN2 Vaccine 2,536 8 0.12 57.5 (7.1, 84.8) 3,916 94 0.87 0.2 (37.0, 26.7)
Control 2,271 18 0.28 3,880 93 0.87
CIN3 Vaccine 2,356 0 0.00 100 (160.1, 100) 3,916 40 0.37 3.2 (57.1, 40.4)
Control 2,271 3 0.05 3,880 41 0.38
a n, number of evaluable women in each group; no. of cases, number of evaluable women reporting at least one event; rate, number of cases divided by sum of follow-up period
(per 100 person-years), where follow-up period started on day after first vaccine dose; TVC, total vaccinated cohort; TVC-naive, total vaccinated cohort of women who at baseline
had no DNA detected for 14 high-risk HPV types, were seronegative for HPV-16 and HPV-18, and had normal cytology results.
b Two CIN3 cases were associated with HPV-33, and one subject had a CIN3 lesion which could not be associated with a high-risk HPV type according to the rules prespecified by
the Endpoint Committee. This subject had a 6-month persistent infection with HPV-58 and a CIN2 lesion associated with HPV-58 preceding the CIN3 diagnosis, suggesting that
HPV-58 might have been involved in the development of the lesion.
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dressed inmore detail in an article byWheeler and colleagues (13).
Virological endpoints have the advantage of not being compli-
cated by infectionwithmultipleHPV types. In youngwomen aged
15 to 17 years, VE against 6-month and 12-month PIs with
HPV-16 and/or -18 was 71% and 66%, respectively, which reflects
the 73% to 75% efficacy observed against CIN1, CIN2, and
CIN3 associated with HPV-16 and/or -18 in this age group in
the TVC. We also observed some cross-protection in 15- to 17-
year-olds against PIs with the combination of nonvaccine hr types
HPV-31/33/45/51. No cross-protection was observed in older age
groups with evidence of past and/or current HPV infection at
baseline (baseline positive cohort).
Multiple infections were commonly associated with CIN2
lesions in the control group of the TVC-naive. Estimates of the
proportion of lesions associated with HPV-16/18 in unvaccinated
women ranged from 31.6% (lesions with only HPV-16 and/or -18
present) to 64.3% (lesions with HPV-16 and/or -18 plus at least
one additional HPV type) for CIN2 and 31.6% to 73.7% for
CIN3. Yet, in the baseline negative subjects, the vaccine pro-
vided high and very high efficacy against bothCIN2 andCIN3
lesions, irrespective of HPV type.
Approximating a sexually naive population has several limita-
tions. HPV serology is not a perfect marker of prior exposure to
HPV infection. Previous studies have shown that approximately
30 to 40% of women with incident HPV-16 infection never have
detectable antibodies (37, 38). Furthermore, serological testing
was not performed for cross-neutralizing antibodies (39). Thus,
cross-protective immunogenicity and prior exposure to nonvac-
cine HPV types were unknown. Similarly, although the PCR used
in this study detected 14 of the most relevant hr HPV types,
women in the TVC-naive could have been infected with other
high-risk types not detected by the specific PCR-based HPVDNA
assays. Therefore, the TVC-naive may have included some young
women who were not truly HPV naive, which would result in an
underestimation of the expected vaccine impact in naive young
adolescents. On the other hand, even among the target population
of young adolescents, some might already be infected with HPV,
for example, through sexual abuse. Other factors which may limit
the extrapolation of the study results were the enrollment of 80%
of 15- to 17-year-olds from a single country (Finland) and the
enrollment of approximately half of the older age groups from
Asia Pacific, although recent data from Scotland have shown the
impact of the HPV-16/18 AS04-adjuvanted vaccine in other pop-
ulations in a real-world setting (40). Additionally, compliance
with the three-dose vaccination schedule was90% in this study,
which is higher than that achieved in most catch-up campaigns,
particularly for older cohorts (19, 41, 42).
In conclusion, this study confirms the widely held view that
targeting young adolescent girls before sexual debut for prophy-
lactic HPV vaccination could have a substantial impact on the
incidence of high-grade cervical abnormalities. Modeling data
predict that anti-HPV-16 and -18 antibodies elicited by the HPV-
16/18 AS04-adjuvanted vaccine will persist for many years after
vaccination, suggesting that vaccinated young girls may be pro-
tected for the most of their sexually active lives (43). Inconsistent
or negligible efficacy was observed for women aged 21 to 25 years,
likely due to a higher proportion of women with prevalent infec-
tions at baseline. This is in linewith analyses suggesting reduced or
negligible cost-effectiveness of vaccination programs in women
aged 21 years and above (36, 44). For women aged 18 to 25 years,
unfortunately neither the models nor our data are conclusive.
There may, however, be individual benefit for vaccination of
HPV-negative women aged 18 years and older.
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